Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

n two large capital projects for which the majority of work has since been completed.  

Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased to finish 2009 at the high end of our prior earnings guidance, with just over $47 million in EBITDA.  We successfully managed working capital and expense levels throughout the business and reduced net debt by nearly $23 million during the year.

"As we entered 2009 the macro-economy suggested a conservative approach that led us to focus on reducing costs and maximizing cash flow.  While the outlook for the economy appears to have stabilized as we start 2010, our smaller customers continue to face a difficult funding environment and pricing pressures continue to exist in most product categories.  The 2010 forecasts for certain of our larger products are lower than we expected, and in some cases lower than 2009, for a variety of reasons.  We renegotiated an extension of an important contract for certain drug delivery products during the fourth quarter, and made price and volume concessions in order to maintain the majority of the share of this business over the next three years.  These are key factors contributing to our guidance of flat to lower sales and profits for 2010.

"We have opportunities to grow revenues through the advancement of projects in our pipeline of late stage development products, within our controlled substances and drug delivery categories and through the launch of new generic APIs.  However, we are convinced that we need to invest more aggressively, both internally and externally, in niche markets, novel technologies, and new geographies that generate sustainable growth.  Of course, we will continue to identify ways to further reduce costs and increase cash flow as we focus on growing the business."

'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
(Date:7/29/2014)... 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... its investment in Green Chemistry and donated more than ... year, the Company announced Monday in its new ... World? The report comes in a ... a responsible corporate citizen, including recognition for the second ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... XR(TM) rosacea-specific study also slated for presentation at American ... NAPA, Calif., March 5 Senetek PLC (OTC ... the development of technologies that target the science of ... launching at the American Academy of Dermatology,s 67th Annual ...
... AMSTERDAM, March 5 ,Agendia, a world leader in ... Albert A. (Al) Luderer to its Supervisory Board. ... more than 30 years of experience in in ... he,is the Chief Executive Officer and President of ...
... Fla., March 5 NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), ... for the fourth quarter and full-year ended December 31, 2008. ... Revenue of $5.9 million, an increase ... 17.2% sequential increase in revenues in Q4 08 vs. Q3 08 ...
Cached Biology Technology:Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 2Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers 3Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 3NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 4NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 5NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 6NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 7NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 8
(Date:7/29/2014)... book that brings together two of the major disciplines ... of insect fossils through stunning photographs and unique illustrations. ... E Jepson, details the incredible preservation and diversity of ... for what these remarkable fossils can tell us about ... of our planet. Like the mosquito in Jurassic Park, ...
(Date:7/28/2014)... of two additional coral communities showing signs of damage from ... the 2010 spill in the Gulf of Mexico. The discovery ... of biology at Penn State University. A paper describing this ... the Gulf of Mexico will be published during the last ... the journal Proceedings of the National Academy of Sciences ...
(Date:7/28/2014)... professor John Essigmann and colleagues from the University of Washington ... if they could induce the virus to mutate uncontrollably, they ... a strategy that our immune system uses against many viruses. ... HIV to mutate at an enhanced rate, as expected. But ... small clinical trial reported in 2011. In a new study, ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... Researchers at the Virginia Bioinformatics Institute at Virginia Tech and ... at 454 Life Sciences of Branford, Conn., have sequenced the ... is a naturally occurring strain of B. abortus ... John Buck in 1923. It has been used for more ...
... eastern spinner dolphins in the eastern tropical Pacific Ocean ... death in the tuna purse-seine fishery between 1960 and ... "These estimates are encouraging because they are consistent ... stocks are recovering, now that reported fishery mortality has ...
... the strange properties of quantum mechanics to the macroscopic ... series of recent developments. The exciting progress was made ... recently at a high level conference organised by the ... Frderung der wissenschaftlichen Forschung in sterreich (FWF) and the ...
Cached Biology News:Brucella abortus S19 genome sequenced; points toward virulence genes 2NOAA study shows eastern tropical pacific ocean dolphin populations improving 2Europe gets together to harness quantum physics 2Europe gets together to harness quantum physics 3Europe gets together to harness quantum physics 4
Request Info...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Biology Products: